SOURCE: Acceleron Equity Research

October 01, 2014 11:32 ET

Coverage Initiation Report Focuses on Pluristem Therapeutics

NEW YORK, NY--(Marketwired - Oct 1, 2014) - Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE: PLTR) is the subject of a new in-depth initiation coverage report by Acceleron Equity Research.

Interested investors may get more information and a copy of the coverage report at

  • PSTI is currently pursuing the development of its PLX cells for 12 different indications that are in various stages of development, from preclinical to Phase II, throughout the world. 

  • The company's proprietary 3-dimensional cell growth methods and manufacturing facility have an estimated $1 billion worth of production capacity per year, setting PSTI apart from the rest of the cell therapy market. 

  • United Therapeutics has licensed the exclusive global rights to PLX cells for the treatment of pulmonary arterial hypertension (PAH) in a deal valued at over $55 million.

  • CHA Bio&Diostech has licensed the rights to PLX cells for the treatment of peripheral artery disease (PAD) in South Korea, with deal terms including a 50/50 joint venture, CHA covering all costs of clinical trials and subsequently sharing post-commercialization profits equally with PSTI.

  • The U.S. National Institutes of Health are working with PSTI on a development program for PLX cells in the treatment of acute radiation syndrome (ARS).

About Acceleron Equity Research

Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.

Contact Information

  • Media Contact:
    Mike Morhamus
    Acceleron Equity Research